Skip to main content
If you are having trouble viewing this message, please click here.
To ensure consistent delivery, please be sure to add us to your address book or your safe senders list.

Advertisement
U.S. Pharmacist Diabetes Update
Advertisement
March 8, 2018
ADA Updates Diagnosis and Classification Standards
Members of the American Diabetes Association's (ADA's) Professional Practice Committee highlight changes in classification and diagnosis in the 2018 Standards of Medical Care in Diabetes. While there are many categories of diabetic diagnoses that most clinicians readily recognize, the ADA reminds healthcare providers that there are still lesser known causes warranting consideration. As diabetic research continues to evolve, limitations of our previous monitoring standards also require greater scrutiny and corrective plan management. Read More.
Diabetes Study Reveals Added Ophthalmic Risks
The risks of uncontrolled diabetes on the eye due to microvascular damage caused by elevated blood glucose are well known. However, a new study highlights additional risks that warrant further consideration and perhaps enhanced screening in diabetic patients. All individuals are at increased risk of cataract formation with advancing age; however, it appears that adults with diabetes over age 40 years are at even greater peril. Read More.
Clinical Trial Assesses Bolus Insulin Dose App
Barriers to using technology to manage diabetes have included concern over the efficacy and reliability of the "newest tools" available. A recent study examines the clinical impact of new speech-recognition software that promotes the goal of modifying bolus doses by calculating a premeal insulin dose based on a voice description of the meal. These findings support the ongoing need to evaluate the efficacy of new technology applications through the use of robust scientific exploration to ensure confidence in both the patient with diabetes and healthcare providers responsible for managing their chronic disease. Read More.

Comments

Popular posts from this blog

ADMELOG A NEW INSULIN  LISPRO OPTION A MEALTIME INSULIN highly similar to Humalog ® in structure, pharmacology, efficacy, safety, and dosing 1-4 FOR DETAILS, VISIT ADMELOGPRO.COM Indication for ADMELOG ® (insulin lispro injection) 100 Units/mL ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adults with type 2 diabetes and adults and children (3 years and older) with type 1 diabetes. Important Safety Information for ADMELOG ® (insulin lispro injection) 100 Units/mL CONTRAINDICATIONS ADMELOG is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin lispro or to any of its excipients. WARNINGS AND PRECAUTIONS Insulin pens and needles must never be shared between patients, even if the needle ...
If you are having trouble viewing this message, please click here . To ensure consistent delivery, please be sure to add us to your address book or your safe senders list. March 14, 2018 Higher Steroids Don’t Prevent Asthma Flare-Ups in Mild/Moderate Pediatric Cases Increasing the dose of inhaled steroids in children with mild/moderate asthma doesn’t have the desired effect and could have unintended consequences, according to a new study.  Here’s why  pharmacists might want to raise a red flag with with too-frequent refills. ...
Recommend OneTouch ® meters with confidence. We’re here to help your patients by offering the lowest co-pay on the most health plans. ‡ * Covered: For most plans, products that are generally available and reimbursed. † Medical exception may apply. ‡ Some health plans may have more than one brand available at the lowest co-pay. The information provided is not a guarantee of coverage or payment. Actual benefits are determined by each plan in accordance with its respective policies and procedures. All trademarks are the property of their respective owners. © 2018 LifeScan, Inc.   NACO/OTB/1016/0468c...